PSYCH Investor Summit: Research & Development - Richard Carleton, Greg McKee + Roger McIntyre скачать в хорошем качестве

PSYCH Investor Summit: Research & Development - Richard Carleton, Greg McKee + Roger McIntyre

The Next 5 to 10 years of Research & Development. The second panel discussion at 7 July’s Psych Investor Summit: Research & Development was forward looking and moderated by Business Insider’s psychedelic industry journalist Yeji Jesse Lee. Richard Carleton, CEO at Canadian Securities Exchange, was joined by Tryp Therapeutics’ CEO and Chairman, Greg McKee and Braxia Scientific’s CEO Roger McIntyre, to examine the market’s roadmap and how investors can best support research and development programmes. About Richard Carleton, CEO at Canadian Securities Exchange: Richard Carleton has been CEO of the Canadian Securities Exchange for seven years. Prior to this appointment, Richard served as Vice-President Corporate Development with responsibility for the CSE’s technology, operations, market data and trading sales teams. About Greg McKee, CEO and Chairman of Tryp Therapeutics: Greg McKee has more than 20 years of biotechnology, life sciences management and leadership and venture investment experience. Before joining Tryp, he founded Torrent Ventures, an early stage digital health and medical technology venture fund, and served as chief executive officer of CONNECT, the largest Southern California start-up accelerator creating and scaling innovative life sciences and technology companies. About Roger McIntyre, CEO at Braxia Scientific: Braxia Scientific CEO Roger McIntyre is a Professor of Psychiatry and Pharmacology at the University of Toronto. McIntyre has been named as one of the “The World’s Most Influential Scientific Minds” by Clarivate Analytics since 2014. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. About Yeji Jesse Lee, Journalist at Business Insider: Yeji Jesse Lee covers psychedelic and cannabis industry news for Business Insider. Once New York became the epicentre of the novel coronavirus earlier this year, she also covered the healthcare industry, interviewing doctors and other healthcare professionals on the frontlines of caring for COVID-19 patients. About PSYCH: PSYCH is a premium business-to-business media and content platform for the psychedelic science and healthcare industry. The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking. To learn more about us, access our industry-leading events, subscribe to the most widely read psychedelics industry newsletter, or view our insight-rich Psychedelics as Medicine Report. Web: https://psych.global/ Twitter:   / psychglobal_   LinkedIn:   / psych%e2%84%a2